System Utilizes Two Wavelengths to Provide a Customizable and
More Comprehensive Treatment Protocol for Patients of All Ages and
Skin Types
LAVAL, QC, March 8, 2021 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its Solta
Medical business, a global leader in the medical aesthetics market,
today announced the U.S. launch of the Clear +
Brilliant® Touch laser, the company's next
generation Clear + Brilliant® laser. The Clear +
Brilliant® Touch laser delivers a customized
and more comprehensive treatment protocol by providing patients of
all ages and skin types the benefits of two wavelengths. By
seamlessly switching between two wavelengths with the Original and
Perméa® handpieces, physicians can now more
easily deliver a more complete treatment during a single
appointment.
"The new innovative features of the Clear +
Brilliant® Touch laser are designed to make the
system easier and more convenient to use. Aesthetic providers can
now more efficiently offer patients a complete treatment using two
wavelengths by seamlessly switching between the Original
and Perméa® handpieces during one
appointment. We believe physicians and their patients will
experience a real advantage with the new Clear +
Brilliant® Touch laser," said Tom Hart,
global vice president, Solta Medical. "As pioneers in the aesthetic
market, Solta Medical has continued to evolve the Clear +
Brilliant® technology to improve upon the efficiency and
convenience that physicians and their patients have come to expect
from Solta Medical."
In addition to offering easy access to both the Original and
Perméa® handpieces in the compact system, the
Clear + Brilliant® Touch laser also includes
a user-friendly touchscreen, a simple training mode to simulate
treatment without emitting laser energy and a smart charting
assistant that automatically tracks treatment progress with the
ability to export patient treatment charts.
"The Clear + Brilliant® laser is an easy-to-use and
transportable system that has been a mainstay in my practice
for years. The new system, the Clear + Brilliant®
Touch laser offers even more versatility, for my
patients. Having the option to use both wavelengths seamlessly
during one appointment will be a welcome addition to my
practice and to my patients," said Jeffrey S. Dover,
M.D., FRCPC, a board-certified dermatologist in Boston, MA.
About the Clear + Brilliant® Laser
Solta
Medical's Clear + Brilliant® laser, which has been a
pioneer in preventative* skin treatments and a leader in the laser
treatment landscape since 2011, has delivered more than 2.5 million
procedures. Supported by robust evidence-based data that includes
more than 15 clinical studies, the Clear + Brilliant®
laser uses fractional laser technology to create structural
and functional changes to the skin, helping to prevent* the early
signs of aging, maintain youthful looking skin and improve the
skin's overall appearance.
For more information on the Clear + Brilliant®
Touch laser, visit www.touch.clearandbrilliant.com/hcp.
About Solta Medical
Solta Medical, part of the Ortho
Dermatologics business of Bausch Health Companies Inc., is a global
leader in the medical aesthetics market that helps drive revenue
growth to aesthetic practices by providing innovative and effective
skin rejuvenation and body contouring solutions. Solta Medical's
vision is to develop and support trusted aesthetic brands that
provide value and lasting growth to physicians and patients. These
include the Thermage® RF systems, Fraxel®
laser, Clear + Brilliant® laser and VASER®
ultrasonic systems. More than six million procedures have been
performed with Solta Medical's portfolio of products around the
world. More information can be found at www.solta.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "believes,"
"estimates," "potential," "target," or "continue" and variations or
similar expressions. These statements are based upon the current
expectations and beliefs of management and are subject to certain
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the
risks and uncertainties discussed in Bausch Health's most recent
annual report on Form 10-K and detailed from time to time in Bausch
Health's other filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. They also include,
but are not limited to, risks and uncertainties caused by or
relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on Bausch
Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
®/TM are trademarks of Bausch Health Companies Inc. or
its affiliates.
Any other product/brand names and/or logos are trademarks of the
respective owners.
© 2021 Bausch Health Companies Inc. or its affiliates.
CBT.0035.USA.21
*Preventative treatment refers to prevention of worsening
of fine lines or wrinkles due to aging or sun
damage.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/solta-medical-announces-the-us-launch-of-the-clear--brilliant-touch-laser-301241902.html
SOURCE Bausch Health Companies Inc.